BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 35169082)

  • 61.
    Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
    Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.
    Wongsurawat T; Jenjaroenpun P; Anekwiang P; Arigul T; Thongrattana W; Jamshidi-Parsian A; Boysen G; Suriyaphol P; Suktitipat B; Srirabheebhat P; Cheunsuchon P; Tanboon J; Nookaew I; Sathornsumetee S
    Brain Pathol; 2024 Jan; 34(1):e13203. PubMed ID: 37574201
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.
    Muzyka L; Goff NK; Choudhary N; Koltz MT
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445633
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
    Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
    Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
    Sonoda Y
    Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IDH clonal heterogeneity segregates a subgroup of non-1p/19q codeleted gliomas with unfavourable clinical outcome.
    Luo S; Zhu S; Liao J; Zhang Y; Hou X; Luo T; Zhao E; Xu J; Pang L; Liang X; Xiao Y; Li X
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):394-405. PubMed ID: 33098109
    [TBL] [Abstract][Full Text] [Related]  

  • 75. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Update on the 2016 WHO classification of tumors of the central nervous system - Part 1: Diffusely infiltrating gliomas].
    Švajdler M; Rychlý B; Zámečník J; Švajdler P
    Cesk Patol; 2017; 53(1):12-21. PubMed ID: 28248117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.